![The Diagnostics Pipeline: FDA Proceeds without Congress Over LDTs Reform](https://www.g2intelligence.com/wp-content/uploads/2023/08/Sept23.DTET_.NewProductsPipeline.formerlyFDAWatch-iStock-1354172420_1100x800-1080x675.jpg)
The Diagnostics Pipeline: FDA Proceeds without Congress Over LDTs Reform
The agency recently sent its own proposed LDTs regulation rule to the White House Office of Information and Regulatory Affairs for review.
The agency recently sent its own proposed LDTs regulation rule to the White House Office of Information and Regulatory Affairs for review.
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
The proposed PFS rule also includes other changes that will affect physician, lab, and other reimbursements in 2024 and beyond.
Recently proposed rule seems too stringent to reduce the lag between FDA approval and Medicare coverage.
An overview of the layoffs announced by major lab diagnostic companies in the first half of 2023 and the key trends.
Owlstone Medical CEO discusses recent trends, the advantages of breath testing, and the challenges that must be met for wider clinical use.
Owlstone Medical CEO Billy Boyle discusses the latest developments in breath biopsy and issues related to its wider clinical adoption.
This webinar will analyze the true cost of using manual paper requisition forms for laboratory testing, highlighting the financial and medical risks involved.
The recent 8-1 decision expands the DOJ’s power to request such cases be thrown out.
Lab staffing expert shares three key strategies for recruiting and retaining talent during difficult economic times.